Introduction: Plasmodium falciparum, the deadly agent of malaria, is notorious for its
capacity to develop drug resistance. Treatment failures of artemisinin therapy regimens …

Antimalarial chemotherapy, globally reliant on artemisinin-based combination therapies
(ACTs), is threatened by the spread of drug resistance in Plasmodium falciparum parasites …

A decline in our ability to successfully treat patients with malaria infections of the parasitic
protozoan Plasmodium falciparum with cheap quinoline drugs has led to a huge escalation …

The emergence and spread of multidrug resistant Plasmodium falciparum has severely
limited the therapeutic options for the treatment of malaria. With ever‐increasing failure rates …

The ability to treat and control Plasmodium falciparum infection through chemotherapy has
been compromised by the advent and spread of resistance to antimalarial drugs. Research …

Emergence of drugs resistant strains of Plasmodium falciparum has augmented the scourge
of malaria in endemic areas. Antimalaria drugs act on different intracellular targets. The …

Chemotherapy is a critical component of malaria control. However, the most deadly malaria
pathogen, Plasmodium falciparum, has repeatedly mounted resistance against a series of …

On the western border of Thailand, Plasmodium falciparum has become resistant to almost
all antimalarial agents. The molecular basis of resistance in these parasite populations has …

Mutations in the chloroquine resistance (CQR) transporter gene of Plasmodium falciparum
(Pf crt; chromosome 7) play a key role in CQR, while mutations in the multidrug resistance …

Drug resistance represents a major obstacle in the radical control of malaria. Drug
resistance can arise in many different ways, but recent developments highlight the …